Janice N. Tieu

Array ( [id] => 16153663 [patent_doc_number] => 20200215064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS [patent_app_type] => utility [patent_app_number] => 16/738103 [patent_app_country] => US [patent_app_date] => 2020-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960327 [patent_doc_number] => 20200163915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS [patent_app_type] => utility [patent_app_number] => 16/736705 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267277 [patent_doc_number] => 20200268764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => APILIMOD COMPOSITIONS AND METHODS FOR USING SAME [patent_app_type] => utility [patent_app_number] => 16/728566 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17104325 [patent_doc_number] => 11124520 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-21 [patent_title] => Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents [patent_app_type] => utility [patent_app_number] => 16/703180 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 12621 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16703180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17267465 [patent_doc_number] => 11192876 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Tricyclic spiro compound [patent_app_type] => utility [patent_app_number] => 16/700522 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27019 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 866 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678259 [patent_doc_number] => 20200093793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETINOPATHY AND OTHER OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 16/697611 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16697611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16326741 [patent_doc_number] => 20200297706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => APILIMOD COMPOSITIONS AND METHODS FOR USING SAME IN THE TREATMENT OF RENAL CANCER [patent_app_type] => utility [patent_app_number] => 16/695814 [patent_app_country] => US [patent_app_date] => 2019-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16695814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16008949 [patent_doc_number] => 20200179317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => COMBINATION THERAPY FOR HEAD AND NECK CANCER [patent_app_type] => utility [patent_app_number] => 16/689965 [patent_app_country] => US [patent_app_date] => 2019-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16689965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695436 [patent_doc_number] => 10946005 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Methods for shrinking pituitary tumors [patent_app_type] => utility [patent_app_number] => 16/678988 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 10 [patent_no_of_words] => 12618 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16678988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15862711 [patent_doc_number] => 20200138759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => PHARMACEUTICALLY ACCEPTABLE SALTS OF BETA-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/675669 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458811 [patent_doc_number] => 20220072115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => MALARIA ANTIGENS ON THE SURFACE OF ERYTHROCYTES AND MEROZOITES AND PROTECTIVE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/289133 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553163 [patent_doc_number] => 20200060993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => CAROTENOID-CONTAINING COGNITIVE FUNCTION IMPROVING COMPOSITION FOR USE IN EXERCISE THERAPY FOR IMPROVING COGNITIVE FUNCTION [patent_app_type] => utility [patent_app_number] => 16/666088 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16666088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504847 [patent_doc_number] => 20200384103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/598900 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16598900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16815730 [patent_doc_number] => 11000529 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Human papilloma virus replication inhibitors [patent_app_type] => utility [patent_app_number] => 16/568310 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8935 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15451147 [patent_doc_number] => 20200038397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => PHARMACOTHERAPY FOR PREVENTING OR TREATING GLAUCOMA [patent_app_type] => utility [patent_app_number] => 16/566473 [patent_app_country] => US [patent_app_date] => 2019-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915277 [patent_doc_number] => 10654867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Heteroaryl estrogen receptor modulators and uses thereof [patent_app_type] => utility [patent_app_number] => 16/565041 [patent_app_country] => US [patent_app_date] => 2019-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42704 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16565041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586323 [patent_doc_number] => 20200069696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => OPHTHALMIC INJECTABLE FORMULATION PREPARING AND OCULOPATHY TREATING AND PREVENTING [patent_app_type] => utility [patent_app_number] => 16/553739 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16553739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16563189 [patent_doc_number] => 10888536 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-01-12 [patent_title] => Method of improvement of insulin sensitivity in obese patients [patent_app_type] => utility [patent_app_number] => 16/553822 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 2075 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16553822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421219 [patent_doc_number] => 11254660 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => Combinations for treatment of NASH/NAFLD and related diseases [patent_app_type] => utility [patent_app_number] => 16/553818 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 31938 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16553818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553171 [patent_doc_number] => 20200060997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => TARR Receptor Agonists for Sexual Dysfunction [patent_app_type] => utility [patent_app_number] => 16/552083 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16552083 [rel_patent_id] =>[rel_patent_doc_number] =>)